within Pharmacolibrary.Drugs.ATC.M;

model M09AX12
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M09AX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Viltolarsen is an antisense oligonucleotide drug designed to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation amenable to exon 53 skipping. It is administered intravenously and was approved by the FDA in August 2020 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in ambulatory pediatric male patients (ages 4 to <10 years) with Duchenne muscular dystrophy after single and multiple intravenous infusions.</p><h4>References</h4><ol><li><p>Komaki, H, Takeshima, Y, Matsumura, T, Ozasa, S, Funato, M, Takeshita, E, Iwata, Y, Yajima, H, Egawa, Y, Toramoto, T, Tajima, M, &amp; Takeda, S (2020). Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study. <i>Annals of clinical and translational neurology</i> 7(12) 2393–2408. DOI:<a href=\"https://doi.org/10.1002/acn3.51235\">10.1002/acn3.51235</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33285037/\">https://pubmed.ncbi.nlm.nih.gov/33285037</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M09AX12;
